Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
Тирзепатид по сравнению с семаглутидом для лечения ожирения
2025-05-11
SCID: 54.1/tjw6sy63
Discuss with AI
Obesity managementSemaglutideTirzepatideWaist circumferenceWeight reduction
Figures from the paper
Abstract (AI)
BACKGROUND: Tirzepatide and semaglutide are highly effective medications for obesity management. The efficacy and safety of tirzepatide as compared with semaglutide in adults with obesity but without type 2 diabetes is unknown. METHODS: In this phase 3b, open-label, controlled trial, adult participants with obesity but without type 2 diabetes were randomly assigned in a 1:1 ratio to receive the maximum tolerated dose of tirzepatide (10 mg or 15 mg) or the maximum tolerated dose of semaglutide (1.7 mg or 2.4 mg) subcutaneously once weekly for 72 weeks. The primary end point was the percent change in weight from baseline to week 72. Key secondary end points included weight reductions of at least 10%, 15%, 20%, and 25% and a change in waist circumference from baseline to week 72. RESULTS: A total of 751 participants underwent randomization. The least-squares mean percent change in weight at week 72 was -20.2% (95% confidence interval [CI], -21.4 to -19.1) with tirzepatide and -13.7% (95% CI, -14.9 to -12.6) with semaglutide (P<0.001). The least-squares mean change in waist circumference was -18.4 cm (95% CI, -19.6 to -17.2) with tirzepatide and -13.0 cm (95% CI, -14.3 to -11.7) with semaglutide (P<0.001). Participants in the tirzepatide group were more likely than those in the semaglutide group to have weight reductions of at least 10%, 15%, 20%, and 25%. The most common adverse events in both treatment groups were gastrointestinal, and most were mild to moderate in severity and occurred primarily during dose escalation. CONCLUSIONS: Among participants with obesity but without diabetes, treatment with tirzepatide was superior to treatment with semaglutide with respect to reduction in body weight and waist circumference at week 72. (Funded by Eli Lilly; SURMOUNT-5 ClinicalTrials.gov number, NCT05822830.).
Key Findings
1
Gastrointestinal adverse events were most common with both treatments, generally mild to moderate, and occurred mainly during dose escalation.
2
In a 72-week phase 3b trial of 751 adults with obesity without type 2 diabetes, tirzepatide produced greater weight loss than semaglutide.
3
Mean waist circumference reduction was -18.4 cm with tirzepatide versus -13.0 cm with semaglutide (P<0.001).
4
Mean weight change at week 72 was -20.2% with tirzepatide versus -13.7% with semaglutide (P<0.001).
5
Participants receiving tirzepatide were more likely to achieve at least 10%, 15%, 20%, and 25% weight loss.
Research Object
Adults with obesity without type 2 diabetes treated with tirzepatide or semaglutide
Research Subject
Comparative efficacy and safety, including reductions in body weight and waist circumference over 72 weeks
Publication Details
Publication Date
2025-05-11
Journal
Publisher
ISSN
Cited by
756
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai5
Once-Weekly Semaglutide in Adults with Overweight or Obesity2021
Tirzepatide Once Weekly for the Treatment of Obesity2022
Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity2024
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity2023
Tirzepatide for Obesity Treatment and Diabetes Prevention2024
Cited by4
Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes2025
Exploring Adults’ Experiences with Tirzepatide for Weight Loss: A Mixed-Methods Study2025
GLP-1 medications: use and interest in a representative survey of Finns2026
Patient perceptions of the efficacy and safety of tirzepatide: Discrepancies with clinical data and limited awareness of cardiovascular benefits2026